Tepotinib, also known as {MSC2156119|the experimental compound|this agent), represents a novel advance in the targeting of NSCLC, particularly in those harboring MET changes. This specific tyrosine kinase inhibitor|TKI https://janasnno601561.blognody.com/49282526/tepotinib-a-in-depth-investigation-into-this-agent-and-its-possibilities